(Boursier.com) — The French biotechnology company genOway shares the latest announcements from its client Sensei Biotherapeutics, an American biotechnology company specializing in immuno-oncology, on the development of its molecule SNS-101 for the treatment of advanced solid tumors.
SNS-101 is a conditionally active human monoclonal IgG1 antibody designed to selectively block the VISTA immune checkpoint (ICP) in the tumor microenvironment, which acts as a T cell suppressor by binding to the PSGL-1 receptor. Following the authorization obtained in April 2023 from the FDA (Food & Drug Administration) to initiate phase 1/2 of its clinical trial for its drug candidate SNS-101, Sensei Biotherapeutics has just announced that a first patient just received his first dose of treatment.
During the preclinical stages that demonstrated the effectiveness of its new molecule, Sensei Biotherapeutics decided to use two Catalog models from genOway. The jointly defined strategy involved testing both on the humanized ICP Vista model and also on the BRGSF-HIS immunodeficient model in which a human immune system has been reconstituted. This crossed approach has made it possible to effectively validate the therapeutic interest of the SNS-101 molecule and to obtain IND (Investigational New Drug Applications) from the FDA in barely 2 years.
This result echoes genOway’s objective of enabling its customers to select the most effective and safest drug candidate. genOway is today the only company to be able to offer a cross approach using both humanized ICP models and also immunodeficient models such as BRGSF-HIS.
This strategy brings many benefits to its customers by allowing:
– to accelerate the passage of their drug candidate towards the clinical phases (in barely two years for the Sensei Biotherapeutics molecule)
– more efficiently sort false positives and false negatives among drug candidates.
“The fruitful collaboration initiated in early 2021 with Sensei Biotherapeutics through cross-over studies using two flagship models from our catalog (VISTA & BRGSF-HIS) enabled our client to quickly access a clinical trial for its drug candidate. This result perfectly illustrates genOway’s ambition to position itself as a benchmark player in the preclinical studies market. We are concentrating our efforts on providing ever more efficient models in order to create maximum added value for our customers”, comments Alexandre Fraichard. , CEO of genOway.
©2023 Boursier.com